Oral News and Research

RSS

Alpha Omega International Dental Fraternity honors Henry Schein Chairman and CEO

Alpha Omega International Dental Fraternity honored Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, Inc., the largest distributor of health care products and services to office-based practitioners, at the Organization's 2010 Annual Sunny Days Convention.

4 Jan 2011

Researchers report estrogen may increase movement of precancerous cells in oral cavity

Head and neck cancer is the sixth most common type of cancer and is on the rise in some demographic groups, including young women without any known risk factors. Now, researchers at Fox Chase Cancer Center report that estrogen may increase the movement of precancerous cells in the mouth and thus promote the spread of the disease within the oral cavity.

4 Jan 2011

Risk-adjusted TTR appears to improve anticoagulation control

Researchers from Boston University School of Medicine and the Bedford VA Medical Center believe that risk-adjusted percent time in therapeutic range should be used as part of an effort to improve anticoagulation control and thus improve patient outcomes.

4 Jan 2011

FDA approves 200 mg formulation of INTELENCE for HIV-1

The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.

3 Jan 2011

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire Pharmaceuticals, Inc. announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

3 Jan 2011

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

New Year resolution: Cosmetic dentistry

This New Year, we can make the same tired resolutions -- start exercising, eat better, stop smoking -- or we can make a resolution that's actually attainable: Smile more. If those last two words send a chill up your spine, you're not alone, says Charles Martin DDS, founder of the Richmond Smile Center.

30 Dec 2010

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010

Intellipharmaceutics granted extension of deadline to regain compliance with Nasdaq Listing Rule

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today announced that the staff of the Nasdaq Stock Market has granted the Company an extension of the deadline to regain compliance with Nasdaq Listing Rule 5550(b).

30 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Merck confirms plans for developing vernakalant drug for atrial fibrillation

Cardiome Pharma Corp. today announced that it has been advised by its partner, Merck, that the current review of vernakalant is complete, and that Merck has informed Cardiome of its next steps in clinical development for vernakalant beginning in 2011.

29 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

King Pharmaceuticals resubmits NDA for REMOXY

King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. today announced that King has resubmitted a New Drug Application for REMOXY® to the U.S. Food and Drug Administration in response to a Complete Response letter received by Pain Therapeutics in December 2008.

28 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

USAID official discusses agency's efforts to address cholera in Haiti

A USAID official said Tuesday that potential violence following the release of Haiti's final presidential election results could interfere with efforts to contain the country's cholera epidemic, CBC News reports. "What we all worry about is if there is violence again and it disrupts for a couple of days," said Mark Ward, acting director of USAID's Office of U.S. Foreign Disaster Assistance. "That's my biggest headache right now," he added.

23 Dec 2010

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.

23 Dec 2010

Oral News and Research

Alpha Omega International Dental Fraternity honors Henry Schein Chairman and CEO

Researchers report estrogen may increase movement of precancerous cells in oral cavity

Risk-adjusted TTR appears to improve anticoagulation control

FDA approves 200 mg formulation of INTELENCE for HIV-1

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Immunitor reports positive safety imm01 clinical trial against tuberculosis

New Year resolution: Cosmetic dentistry

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Intellipharmaceutics granted extension of deadline to regain compliance with Nasdaq Listing Rule

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Merck confirms plans for developing vernakalant drug for atrial fibrillation

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

King Pharmaceuticals resubmits NDA for REMOXY

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

USAID official discusses agency's efforts to address cholera in Haiti

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News